Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma
April 15th, 2022
4.4K views
Here, we present a protocol for improving the success of interphase fluorescence in situ hybridization detection on bone marrow smears from multiple myeloma patients.
Overview
This article presents a protocol for enhancing the effectiveness of interphase fluorescence in situ hybridization (FISH) detection on bone marrow smears from multiple myeloma patients. The study emphasizes the importance of accurately identifying clonal plasma cells for effective diagnosis.
Key Study Components
Area of Science
- Neuroscience
- Oncology
- Genetics
Background
- Fluorescence In Situ Hybridization (FISH) is crucial for genetic risk stratification in multiple myeloma.
- Clonal plasma cells must be specifically identified for accurate FISH reporting.
- Current methods have limitations, including complexity and high costs.
- Bone marrow smears can facilitate quicker identification of plasma cells.
Purpose of Study
- To improve the detection of multiple myeloma cells using bone marrow smear FISH.
- To address the shortcomings of existing FISH methods.
- To streamline the process of identifying clonal plasma cells.
Methods Used
- Utilization of anti-CD138 magnetic beads for plasma cell sorting.
- Implementation of cytoplasmic kappa or lambda light chain immunoglobulin marking.
- Application of interphase FISH after plasma cell sorting.
- Use of bone marrow smear FISH for efficient detection.
Main Results
- Bone marrow smear FISH effectively identifies multiple myeloma cells.
- Improved accuracy in diagnosing multiple myeloma through targeted plasma cell detection.
- Reduction in specimen demands and experimental costs compared to traditional methods.
- Enhanced protocol facilitates quicker diagnosis and treatment planning.
Conclusions
- The study presents a viable alternative for detecting multiple myeloma cells.
- Bone marrow smear FISH can overcome limitations of existing FISH techniques.
- Future research may focus on further optimizing this method for clinical use.
Frequently Asked Questions
What is the significance of FISH in multiple myeloma?
FISH is essential for genetic risk stratification and accurate diagnosis of multiple myeloma.
How does bone marrow smear FISH improve detection?
It allows for quicker identification of plasma cells, reducing specimen demands and costs.
What are the limitations of traditional FISH methods?
Traditional methods can be complex, costly, and require high specimen amounts.
What is the role of anti-CD138 magnetic beads?
They are used for sorting clonal plasma cells to enhance FISH accuracy.
Can this method be used in clinical settings?
Yes, the improved protocol aims to facilitate clinical diagnosis and treatment planning.
What future research directions are suggested?
Further optimization of the bone marrow smear FISH method for broader clinical application.
Executive Industry Relevance
This method addresses a key bottleneck in multiple myeloma diagnostics by enabling FISH analysis on readily available bone marrow smears, reducing reliance on fresh heparinized aspirates. It supports faster, more accessible genetic risk stratification in hematology oncology pipelines, particularly when sample acquisition is challenging. The approach enhances translational continuity by improving specimen feasibility without compromising clonal plasma cell specificity.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of chromosomal abnormalities in clonal plasma cells directly from smears, supporting mechanistic de-risking of genomic targets.
- Operational Value: Reduces specimen processing complexity by eliminating the need for cell sorting or enrichment prior to FISH.
Screening & Assay Development
- Scientific Value: Provides a standardized, smear-based platform for interphase FISH that improves assay readiness in low-yield or difficult-to-obtain samples.
- Operational Value: Increases reproducibility by minimizing pre-analytical variables associated with fresh aspirate handling and processing.
Translational & Preclinical Research
- Scientific Value: Supports biomarker-aligned studies by preserving spatial context of plasma cells in smears, enabling correlation of morphology with genetic aberrations.
- Operational Value: Facilitates longitudinal monitoring in preclinical models where repeated bone marrow aspiration is impractical.
Pipeline & Workflow Integration
The method fits within the discovery-to-translational continuum by providing a feasible FISH workflow when primary samples are limited, enabling downstream genetic analysis without delaying lead identification or preclinical validation.
- Discovery Biology: Supports hypothesis testing of clonal genomic alterations by allowing FISH on archival or difficult-to-process marrow smears.
- Screening: Enhances assay standardization by using smears as a consistent substrate for hybridization and signal detection.
- Analytics: Enables quantitative assessment of chromosomal copy number changes (e.g., TP53, CEP17) in interphase nuclei, informing risk stratification.
- Translational Research: Maintains continuity from discovery to preclinical validation by allowing repeated sampling via smears in longitudinal studies.
- Enterprise Reuse: Establishes a reusable FISH-ready smear protocol applicable across multiple myeloma models and sample types.
Operational & Enterprise Impact
- Scientific Value: Improves predictive confidence in genomic risk assessment by enabling FISH on samples otherwise unsuitable for analysis.
- Operational Value: Increases laboratory throughput and reduces turnaround time by simplifying specimen preparation.
- Strategic Value: Reduces biological and technical risk in early decision-making by expanding access to critical cytogenetic data.
- Portfolio Impact: Supports risk-adjusted advancement by making FISH-based stratification feasible in resource-constrained or clinical settings.
Implementation Considerations
- Requires expertise in FISH probe design, hybridization, and fluorescence microscopy for accurate signal interpretation.
- Dependent on access to standard FISH equipment including hybridization chambers, wash buffers, and filter sets for DAPI, spectrum green, and spectrum orange.
- Necessitates standardization of smear preparation and staining protocols to ensure consistent plasma cell morphology and retention.
- Must account for variability in plasma cell density across smears when determining sampling depth and signal quantification thresholds.
- Limited to interphase analysis; does not support metaphase karyotyping or structural rearrangement detection without additional methods.
Biopharma FAQs
Why is plasma cell specificity important in FISH for myeloma?
Because malignant plasma cells are rare in bone marrow, FISH must target clonal populations to avoid false-negative or diluted signals from non-neoplastic cells.
How does using bone marrow smears improve FISH feasibility?
Smears are easier to obtain than aspirates, require no anticoagulation, and can be prepared quickly, enabling FISH in cases of dry tap or low-yield samples.
What quantitative measurements does interphase FISH enable in plasma cells?
It allows enumeration of chromosomal signals per nucleus, such as detecting tetrasomy of chromosome 17 via four TP53 and four CEP17 signals in myeloma cells.
Why are replication and consistency important in smear-based FISH?
Uniform smear preparation and hybridization conditions ensure reliable signal detection across samples, supporting cross-laboratory comparability and assay validation.
What analytical capabilities are needed before implementing smear FISH?
Laboratories must be able to perform probe hybridization, signal separation via fluorescence filtering, and co-localization analysis to distinguish true genetic gains from overlap artifacts.
